“I was shocked, as everyone in the scientific community probably were,” says Eduardo López-Medina, a paediatrician at the Centre for the Study of Paediatric Infections in Cali, Colombia, who was not involved with the study and who has investigated whether ivermectin can improve COVID-19 symptoms. “It was one of the first papers that led everyone to get into the idea ivermectin worked” in a clinical-trial setting, he adds.
Latin America’s embrace of an unproven COVID treatment is hindering drug trials....
The paper summarized the results of a clinical trial seeming to show that ivermectin can reduce COVID-19 death rates by more than 90%[SUP]
1[/SUP] — among the largest studies of the drug’s ability to treat COVID-19 to date. But on 14 July, after
internet sleuths raised concerns about plagiarism and data manipulation, the preprint server Research Square withdrew the paper because of “ethical concerns”.